Literature DB >> 19623656

Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance.

Xi Zhu1, Lin-Lin Ma, Tian Ye.   

Abstract

To evaluate the expressions of CD4(+)CD25(high)CD127(low/-) regulatory T cells (Tregs) in peripheral blood from patients with transitional cell carcinoma (TCC) in urinary system, we investigated the proportion of Treg population in CD4(+) T from 93 patients with TCC, 38 with benign urinary diseases, and 37 healthy subjects by using flow cytometric analysis and analyzing different clinicopathologic characteristics and the changes before and after operation. We found that the proportion of Treg in peripheral blood from patients with TCC was significantly increased as compared with the other two groups. There was a strong correlation between the proportion of Treg and tumor recurrence, quantity, lymph node metastasis (P<0.01), as well as pathological stage; no correlation was found between the proportion of Treg and clinical TNM stage (P>0.05). The proportion of Treg was also different before and after operation (P<0.05). This suggest that CD4(+)CD25(+)CD127(low/-) regulatory T cells may be responsible for immune suppression in TCC patients. The resection of tumor can decrease the proportion of Treg in peripheral blood.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19623656      PMCID: PMC6649147          DOI: 10.1002/jcla.20331

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  12 in total

1.  Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells.

Authors:  Dennis J Hartigan-O'Connor; Chungkee Poon; Elizabeth Sinclair; Joseph M McCune
Journal:  J Immunol Methods       Date:  2006-11-03       Impact factor: 2.303

2.  Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.

Authors:  Andrew G Jarnicki; Joanne Lysaght; Stephen Todryk; Kingston H G Mills
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

3.  Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.

Authors:  Christophe Dercamp; Karine Chemin; Christophe Caux; Giorgio Trinchieri; Alain P Vicari
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

4.  Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines.

Authors:  Angelica Loskog; Christina Ninalga; Gabriella Paul-Wetterberg; Manuel de la Torre; Per-Uno Malmström; Thomas H Tötterman
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

5.  Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.

Authors:  Junko Yokokawa; Vittore Cereda; Cinzia Remondo; James L Gulley; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

6.  Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma.

Authors:  A Sasaki; F Tanaka; K Mimori; H Inoue; S Kai; K Shibata; M Ohta; S Kitano; M Mori
Journal:  Eur J Surg Oncol       Date:  2007-10-10       Impact factor: 4.424

Review 7.  Regulatory T cells and treatment of cancer.

Authors:  Tyler J Curiel
Journal:  Curr Opin Immunol       Date:  2008-05-27       Impact factor: 7.486

8.  Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.

Authors:  Sajjan Mittal; Neil A Marshall; Linda Duncan; Dominic J Culligan; Robert N Barker; Mark A Vickers
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

9.  CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.

Authors:  Li-Song Shen; Jian Wang; Ding-Feng Shen; Xiang-Liang Yuan; Ping Dong; Mei-Xing Li; Jian Xue; Feng-Min Zhang; Hai-Liang Ge; Dakang Xu
Journal:  Clin Immunol       Date:  2009-01-18       Impact factor: 3.969

10.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors:  François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

View more
  4 in total

1.  Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement.

Authors:  Samantha Drennan; Nicholas D Stafford; John Greenman; Victoria L Green
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

2.  Prognostic significance of CD4-positive regulatory T cells in tumor draining lymph nodes from patients with bladder cancer.

Authors:  Ali Ariafar; Yasmin Vahidi; Maryam Fakhimi; Ardalan Asadollahpour; Nasrollah Erfani; Zahra Faghih
Journal:  Heliyon       Date:  2020-12-01

3.  Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer.

Authors:  Chan-Zhen Liu; Li Zhang; Xiao-Hong Chang; Ye-Xia Cheng; Hong-Yan Cheng; Xue Ye; Tian-Yun Fu; Jun Chen; Heng Cui
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

4.  Effect of the novel influenza A (H1N1) virus in the human immune system.

Authors:  Evangelos J Giamarellos-Bourboulis; Maria Raftogiannis; Anastasia Antonopoulou; Fotini Baziaka; Pantelis Koutoukas; Athina Savva; Theodora Kanni; Marianna Georgitsi; Aikaterini Pistiki; Thomas Tsaganos; Nikolaos Pelekanos; Sofia Athanassia; Labrini Galani; Efthymia Giannitsioti; Dimitra Kavatha; Flora Kontopidou; Maria Mouktaroudi; Garyfallia Poulakou; Vissaria Sakka; Periklis Panagopoulos; Antonios Papadopoulos; Kyriaki Kanellakopoulou; Helen Giamarellou
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.